How Next-Generation MRD Will Reshape Oncology Drug Development and Treatment Paradigms

Session details:

Minimal residual disease (MRD) has traditionally been used as a surveillance tool, but advances in next-generation sequencing, particularly ultra-sensitive circulating tumor DNA (ctDNA) detection technologies, are unlocking its broader potential as a precision medicine tool to actively guide cancer treatment and accelerate clinical development.

In this session, John Truesdell, Chief Business Officer at Foresight Diagnostics, will explore how next-generation MRD assays will drive both advances in novel therapeutic development and real-time clinical decision making to improve patient outcomes. 

Drawing from Foresight’s academic and biopharma partnerships, this discussion will: 

• Demonstrate how MRD can unlock personalized treatment approaches for patients at high risk of relapse
• Explore the opportunity of MRD as a surrogate endpoint to accelerate trials, especially in novel modalities like CAR T
• Highlight clinical trials today where MRD is enabling response-adapted treatment strategies in lymphoma